Download PDF
Thromb Haemost 1995; 74(02): 626-630
DOI: 10.1055/s-0038-1649788
Original Article
Clinical Studies
Schattauer GmbH Stuttgart

von Willebrand Factor, Soluble P-Selectin, Tissue Plasminogen Activator and Plasminogen Activator Inhibitor in Atherosclerosis

A D Blann
1   The Department of Surgery, University Hospital of South Manchester, Manchester, UK
,
M Dobrotova
2   The Department of Haematology and Blood Transfusion, Jessenius Medical Faculty, Comenius University, Martin’s Faculty Hospital, Martin, Slovak Republic
,
P Kubisz
2   The Department of Haematology and Blood Transfusion, Jessenius Medical Faculty, Comenius University, Martin’s Faculty Hospital, Martin, Slovak Republic
,
C N McCollum
1   The Department of Surgery, University Hospital of South Manchester, Manchester, UK
› Author Affiliations
Further Information

Publication History

Received 15 November 1994

Accepted after resubmission 14 March 1995

Publication Date:
04 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Tissue plasminogen activator antigen (tPA), plasminogen activator inhibitor antigen (PAI-1), soluble P-selectin and von Willebrand factor antigen (vWf) were measured by ELISA in 41 patients with peripheral vascular disease (PVD), 41 with ischaemic heart disease (IHD) and in 46 age and sex matched asymptomatic controls. Increased vWf was found in patients with IHD (p = 0.0002) and in patients with PVD (p = 0.0011) relative to the controls but levels did not differ between the two patients groups. Raised tPA found in both PVD (p = 0.0006) and IHD (p = 0.0061) compared to the controls also failed to differentiate the two groups of patients. Soluble P-selectin was also raised in both groups (p = 0.003 in IHD and p = 0.0102 in PVD) with no difference between the groups. There were no differences in levels of PAI-1 between the groups. In the subjects taken as a whole, there were significant Spearman’s correlations between tPA and vWf (r = 0.37, p <0.001), tPA and triglycerides (r = 0.38, p <0.001), tPA and P-selectin (r = 0.19, p = 0.032), vWf and age (r = 0.25, p = 0.005) and inversely between vWf and HDL (r = -0.25, p = 0.006). These data support the concept that increased levels of tPA may be important in atherosclerosis, and indicate that soluble P-selectin may be useful in further analysis of the role of platelets and the endothelial cell in this disease.

 

  • References

  • 1 Borsum T. Biochemical properties of vascular endothelial cells. Virchows Archiv B Cell Pathol 1991; 60: 279-286
    CrossrefPubMedGoogle Scholar
  • 2 Hekman CM, Loskutoff DJ. Fibrinolytic pathways and the endothelium. Seminars Thromb Haemost 1987; 13: 514-527
    PubMedGoogle Scholar
  • 3 Loscalzo J, Braunwald E. Tissue plasminogen activator. N Engl J Med 1988; 319: 925-931
    CrossrefPubMedGoogle Scholar
  • 4 Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: A review. Atherosclerosis 1992; 95: 105-17
    CrossrefPubMedGoogle Scholar
  • 5 Nilsson TK, Boman K, Bjerle P, Hallamns G, Hellsten G. von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome. J Int Med 1994; 235: 419-423
    CrossrefPubMedGoogle Scholar
  • 6 Hamsten A, Faire U de, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-8
    PubMedGoogle Scholar
  • 7 Blann AD. von Willebrand factor and the endothelium in vascular disease. Br J Biomed Sci 1993; 50: 125-134
    PubMedGoogle Scholar
  • 8 Blann AD, McCollum CN. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemost 1994; 72: 151-154
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Wagner DD. The Weibel-Palade body: the storage granule for von Willebrand factor and P-selectin. Thromb Haemost 1993; 70: 105-110
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Gearing AJ H, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506-512
    CrossrefPubMedGoogle Scholar
  • 11 Springer TA. Adhesion receptors of the immune system. Nature 1990; 346: 425-434
    CrossrefPubMedGoogle Scholar
  • 12 Geng JG, Bevilacqua MP, Moore KL, McIntyre TM, Prescott SM, Kim JM, Bliss GA, Zimmerman GA, McEver RP. Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature 1990; 313: 757-760
    PubMedGoogle Scholar
  • 13 Gralnick HR. von Willebrand’s disease. In: Disorders of Haemostasis. Ratnoff OD, Forbes CD. (eds) Philidelphia: WB Saunders; 1991: 203-244
    Google Scholar
  • 14 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809
    CrossrefPubMedGoogle Scholar
  • 15 Mustard JF, Packham MA. The role of blood and platelets in atherosclerosis and the complications of atherosclerosis. Thromb Diathes Haemorrh 1975; 33: 444-56
    PubMedGoogle Scholar
  • 16 Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH. Atherosclerosis plaque rupture and thrombosis; Evolving concepts. Circulation 1990; 82 Suppl (Suppl. 02) II-47-II-59
    PubMedGoogle Scholar
  • 17 van Zanten GH, de Graaf S, Slootweg PJ, Heijnen HF G, Connolly TM, de Groot PG, Sixma JJ. Increased platelet deposition on atherosclerotic coronary arteries. J Clin Invest 1994; 93: 615-632
    CrossrefPubMedGoogle Scholar
  • 18 Seigneur M, Dufourc P, Conri C, Constans J, Mercie P, Pruvost A, Amiral J, Midy D, Baste JC, Boisseau MR. Levels of plasma thrombomodulin are increased in atheromatous arterial disease. Thrombosis Res 1993; 71: 423-431
    CrossrefPubMedGoogle Scholar
  • 19 Hellsten G, Boman K, Bjerle P, Blom P, Nilsson TK. Increased plasminogen activator inhibitor and tissue plasminogen activator levels in subjects with electrocardiographic abnormality indicative of ischaemic heart disease: a cross sectional study in Norsjo, Sweden. Eur Heart J 1992; 13: 57-60
    PubMedGoogle Scholar
  • 20 Oseroff A, Krishnamurti C, Hassett A, Tang D, Alving B. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. J Lab Clin Med 1989; 113: 88-93
    PubMedGoogle Scholar
  • 21 Speiser W, Speiser P, Minar E, Kominger C, Neissner H, Huber K, Schemthaner G, Ehringer H, Lechner K. Activation of coagulation and fibrinolysis in patients with arteriosclerosis: Relation to localisation of vessel disease and risk factors. Thrombosis Res 1990; 59: 77-88
    CrossrefPubMedGoogle Scholar
  • 22 Prins MH, Hirsh J. A critical review of the relationship between impaired fibrinolysis and myocardial infarction. Am Heart J 1991; 122: 545-551
    CrossrefPubMedGoogle Scholar
  • 23 Munkvad S, Jespersen J, ram J, Kluft C. Interrelationship between coagulant activity and tissue type plasminogen activator (t-PA) system in acute ischaemic heart disease. Possible role of the endothelium J Int Med 1990; 228: 361-366
    CrossrefPubMedGoogle Scholar
  • 24 Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G. et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischaemic events in atherosclerosis patients. A case control study The PLAT group Arteriosclerosis Thromb 1993; 13: 1412-1417
    CrossrefPubMedGoogle Scholar
  • 25 Kunzendorf U, Notter M, Hock H, Distler A, Diamantstein T, Walz G. T cells bind to the endothelial adhesion molecule GMP-140 (P-selectin). Transplantation 1993; 56: 1213-1217
    CrossrefPubMedGoogle Scholar
  • 26 Hamburger SA, McEver RP. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood 1990; 75: 550-554
    PubMedGoogle Scholar
  • 27 Parmentier S, McGregor L, Catimel B, Leung LL K, McGregor JL. Inhibition of platelet functions by a monoclonal antibody (LYP20) directed against a granule membrane glycoprotein (GMP-140/PADGEM). Blood 1991; 77: 1734-1739
    PubMedGoogle Scholar
  • 28 Wong CS, Gamble JR, Skinner MP, Lucas CM, Berndt MC, Vadas MA. Adhesion protein GMP140 inhibits superoxide anion release by human neutrophils. Proc Natl Acad Sci USA 1991; 88: 2397-2401
    CrossrefPubMedGoogle Scholar
  • 29 Gamble JR, Skinner MP, Berndt MC, Vadas MA. Prevention of activated neutrophil adhesion to endothelium by soluble adhesion protein GMP 140. Science 1990; 249: 414-417
    CrossrefPubMedGoogle Scholar
  • 30 Wada H, Minamikawa K, Wakita Y, Nakase T, Kaneko T, Ohiwa M, Tamaki S, Deguchi K, Shirakawa S, Hayashi T, Suzuki K. Increased vascular endothelial cell markers in patients with disseminated intravascular coagulation. Am J Haem 1993; 44: 85-88
    PubMedGoogle Scholar
  • 31 Takahashi H, Ito S, Hanano M, Wada K, Niwano H, Seki Y, Shibata A. Circulatingthrombodulin as a novel endothelial cell marker: Comparison of its behaviour with von Willebrand factor and tissue type plasminogen activator. Am J Haem 1992; 41: 32-39
    PubMedGoogle Scholar
  • 32 Wada H, Keneko T, Ohiwa Tanigawa M, Hayashi T, Tamaki S, Minami N, Deguchi K, Suziki K, Nakaon T, Shirakawa S. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. Am J Haem 1993; 44: 101-105
    PubMedGoogle Scholar
  • 33 Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EK O. Localisation and production of plasminogen activator inhibitor-1 in human healthy and atherosclerosis arteries. Arteriosclerosis Thromb 1993; 13: 1090-1100
    CrossrefPubMedGoogle Scholar
  • 34 Wang DL, Pan YT, Wang JJ, Cheng CH, Liu CY. Demonstration of a functionally active tPA-like plasminogen activator in human platelets. Thromb Haemost 1994; 71: 493-498
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Torr-Brown SR, Sobel BE. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thrombosis Res 1993; 413-421
    PubMedGoogle Scholar
  • 36 Blann AD, Tabemer DA. A reliable marker of endothelial cell dysfunction: does it exist. Br J Haem 1995; 90: 244-248
    CrossrefPubMedGoogle Scholar
  • 37 Collins PW, Macey MG, Cahill MR, Newland AC. von Willebrand factor release and P-selectin expression is stimulated by thrombin and trypsin but not IL-1 in cultured human endothelial cells. Thromb Haemost 1993; 70: 346-350
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Miller GJ, Miller NE. Plasma high density lipoprotein concentration and development of ischaemic heart disease. Lancet 1975; 1: 16-19
    PubMedGoogle Scholar
  • 39 Gershlick AH. Are there markers of the blood-vessel wall interaction and of thrombus formation that can be used clinically. Circulation 1990; 81 Suppl (Suppl. 01) I-28-I-34
    PubMedGoogle Scholar